Barclays Lowers Surgery Partners (NASDAQ:SGRY) Price Target to $14.00

Surgery Partners (NASDAQ:SGRY) had its price objective cut by equities research analysts at Barclays from $18.00 to $14.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective would suggest a potential downside of 0.57% from the stock’s previous close.

Other equities research analysts also recently issued research reports about the stock. Benchmark lowered their price objective on shares of Surgery Partners from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, November 11th. Mizuho reduced their price target on shares of Surgery Partners from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Thursday, December 18th. Royal Bank Of Canada dropped their price objective on shares of Surgery Partners from $35.00 to $31.00 and set an “outperform” rating on the stock in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Surgery Partners in a research report on Monday, December 29th. Finally, UBS Group decreased their target price on Surgery Partners from $34.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Surgery Partners currently has a consensus rating of “Moderate Buy” and an average target price of $25.90.

Surgery Partners Stock Up 1.1%

SGRY stock opened at $14.08 on Tuesday. The stock has a market capitalization of $1.82 billion, a price-to-earnings ratio of -22.71 and a beta of 1.95. The company has a 50-day moving average of $15.28 and a two-hundred day moving average of $18.24. Surgery Partners has a 52-week low of $12.25 and a 52-week high of $24.64. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.87 and a quick ratio of 1.72.

Surgery Partners (NASDAQ:SGRY) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.19). The business had revenue of $885.00 million for the quarter, compared to analyst estimates of $866.54 million. Surgery Partners had a positive return on equity of 1.28% and a negative net margin of 2.35%.Surgery Partners’s revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.44 EPS. As a group, equities research analysts anticipate that Surgery Partners will post 0.67 EPS for the current year.

Surgery Partners announced that its Board of Directors has authorized a stock repurchase plan on Thursday, February 26th that allows the company to buyback $200.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 9.7% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its shares are undervalued.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Groupe la Francaise lifted its position in shares of Surgery Partners by 26.6% during the 2nd quarter. Groupe la Francaise now owns 186,088 shares of the company’s stock worth $4,137,000 after buying an additional 39,089 shares during the period. GABELLI & Co INVESTMENT ADVISERS INC. raised its stake in Surgery Partners by 87.9% during the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 146,250 shares of the company’s stock worth $3,251,000 after acquiring an additional 68,400 shares in the last quarter. AYAL Capital Advisors Ltd acquired a new position in Surgery Partners during the second quarter worth $2,779,000. Norges Bank bought a new position in shares of Surgery Partners during the second quarter valued at $26,609,000. Finally, Gabelli Funds LLC boosted its stake in shares of Surgery Partners by 117.3% in the 2nd quarter. Gabelli Funds LLC now owns 315,002 shares of the company’s stock valued at $7,002,000 after purchasing an additional 170,057 shares in the last quarter.

Key Surgery Partners News

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Board authorized a $200 million share repurchase (up to ~9.7% of shares), signaling management believes the stock is undervalued and should support EPS/float reduction over time. RTT News
• Positive Sentiment: Acquisition: Surgery Partners is buying Preferred Vascular Group (PVG), an ASC operator focused on dialysis-access procedures (8 ASCs in GA and OH). This expands SGRY’s ASC footprint in a specialized, recurring-procedure niche and could drive incremental revenue and cross-selling opportunities. PR Newswire
• Neutral Sentiment: Q4 2025 materials published — earnings call transcript and presentation are available; they detail a mixed quarter (revenue up y/y, EPS miss) and management commentary that investors should review for margin trends and case-volume guidance. Use the transcripts to assess forward cadence. Earnings Call Transcript
• Negative Sentiment: Analyst pressure: Barclays cut its price target from $18 to $14 and moved to an “equal weight” rating, reducing a key buy-side endorsement and potentially dampening near-term demand. Benzinga
• Negative Sentiment: Shareholder litigation inquiry: Johnson Fistel announced an investigation into potential claims against Surgery Partners’ executives, which can create legal risk, distraction, and potential future costs. GlobeNewswire
• Negative Sentiment: Updated FY2026 guidance appeared soft versus consensus (revenue guidance noted roughly $3.4–3.5B vs. consensus ~$3.5B; EPS guidance was unclear in the release), which may raise questions about margin outlook and growth assumptions. Investors should await clarified guidance or management commentary.

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.